MGMT and glioblastoma: Thus, this phase IB of our BORTEM‐17 clinical trial (NCT03643549) was launched to investigate whether pretreatment of recurrent GBM patients with BTZ 1.3 mg/m2 on days 1, 4, and 7, to deplete MGMT levels 48 hours before TMZ, commencing on days 3 to 7 every 4th week, might sensitize MGMT unmethylated GBM to TMZ chemotherapy.